oxybutynin has been researched along with Dermatitis, Contact, Phototoxic in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hogan, DJ | 1 |
| Saenz, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers[NCT01119651] | Phase 1 | 59 participants (Actual) | Interventional | 2010-06-14 | Completed | ||
| A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers[NCT01115322] | Phase 1 | 38 participants (Actual) | Interventional | 2010-04-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for oxybutynin and Dermatitis, Contact, Phototoxic
| Article | Year |
|---|---|
Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies.
Topics: Adolescent; Adult; Aged; Dermatitis, Photoallergic; Dermatitis, Phototoxic; Dosage Forms; Female; Hu | 2012 |
Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies.
Topics: Adolescent; Adult; Aged; Dermatitis, Photoallergic; Dermatitis, Phototoxic; Dosage Forms; Female; Hu | 2012 |
Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies.
Topics: Adolescent; Adult; Aged; Dermatitis, Photoallergic; Dermatitis, Phototoxic; Dosage Forms; Female; Hu | 2012 |
Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies.
Topics: Adolescent; Adult; Aged; Dermatitis, Photoallergic; Dermatitis, Phototoxic; Dosage Forms; Female; Hu | 2012 |